Dr. Jeff Mulchahey Joins Clinilabs as Chief Development Officer

2022-11-08T21:15:07+00:00November 8th, 2022|

EATONTOWN, NJ, November 8, 2022 – Clinilabs Drug Development Corporation (“Clinilabs”), a leading global, full-service CNS CRO, today announced that Dr. Jeff Mulchahey has joined the company as Chief Development Officer (CDO).

Dr. Mulchahey will continue to expand Clinilabs’ presence as a global leader in the management of phase 2 and 3 CNS clinical trials, providing leadership and strategy to help customers optimize their clinical development programs.  Dr. Mulchahey will work closely with Clinilabs’ senior management and across functional service lines to align our offerings with the needs of our customers.  His day-to-day involvement in trial delivery will assure that our pharma and biotech customers receive the highest standard of service available in the industry today.  Dr. Mulchahey reports to Dr. Gary Zammit, CEO of Clinilabs, who commented: “We are pleased to welcome Jeff to our senior management team.  He fills an opening that has been vacant for some time; one that was awaiting the arrival of a dynamic leader with a superior understanding of CNS drug development, service delivery, and performance excellence.”

Dr. Mulchahey brings over 20 years experience of drug development across academia, pharma, and the CRO industry, with an extensive focus in the CNS therapeutic area. He most recently served as Senior Vice President of Clinical Development and Therapeutic Area Lead for Neurology at Syneos Health. In that role, he was responsible for all aspects of the neurology clinical development portfolio, including business development and project delivery.  Dr. Mulchahey has been the senior lead of more than 40 multinational phase 2 and phase 3 trials in North America, Europe, Asia, and Australia which have contributed to approvals of new treatments in a wide array of CNS indications, including psychiatric, neurological, and rare CNS disease indications.  He brings a global perspective to the development of neurotherapeutics that will prove to be an invaluable asset to Clinilabs and our customers.

Dr. Mulchahey comments: “I am very excited to be joining Dr. Zammit and Clinilabs.  We share a vision of excellence in clinical trial delivery combined with an acute focus on CNS indications.  I am passionate about the CNS drug development enterprise and am looking forward to working with our customers on an individual basis as we strive together to develop new treatments to meet the needs of our patients.  This is a particularly exciting time in CNS drug development as the recognition of heterogeneous mechanisms, underlying diseases, and new molecular targeting technologies demand increasing specialization within CNS drug development.  Clinilabs is well positioned to meet the increasingly complex and individual needs of our customers and our patients both now and in the future.”

Dr. Mulchahey will be joining Dr. Zammit and other leaders from Clinilabs at the CNS Summit in Boca Raton, FL later this month.  Please come meet them and learn about our unique perspective and capabilities in CNS drug development.